



Gocovri® (amantadine) – New indication

- On February 1, 2021, [Adamas Pharma announced](#) the FDA approval of [Gocovri \(amantadine\)](#), as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
- Gocovri is also approved for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- Data from two pivotal, placebo-controlled clinical studies showed that treatment with Gocovri significantly reduced both “off” time and dyskinesia. This resulted in a clinically meaningful increase in good “on” time in patients taking a levodopa-based medication for Parkinson’s disease. Additionally, Gocovri demonstrated sustained efficacy for at least two years in the open-label EASE LID-2 study.
- The initial daily dosage of Gocovri is 137 mg, administered orally once daily at bedtime. After one week, the dosage should be increased to the recommended 274 mg (two 137 mg capsules) once daily at bedtime. Gocovri is not interchangeable with other amantadine immediate- or extended-release products.
 - It is recommended to avoid sudden discontinuation of Gocovri.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.